JPWO2020201038A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020201038A5 JPWO2020201038A5 JP2021557778A JP2021557778A JPWO2020201038A5 JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin mutein
- lipocalin
- medicament according
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000019298 Lipocalin Human genes 0.000 claims description 93
- 108050006654 Lipocalin Proteins 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 210000002345 respiratory system Anatomy 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 230000009285 allergic inflammation Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 102000047202 human LCN2 Human genes 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826767P | 2019-03-29 | 2019-03-29 | |
| US62/826,767 | 2019-03-29 | ||
| EP19166435 | 2019-04-01 | ||
| EP19166435.8 | 2019-04-01 | ||
| EP19175818.4 | 2019-05-22 | ||
| EP19175818 | 2019-05-22 | ||
| EP19177568.3 | 2019-05-31 | ||
| EP19177568 | 2019-05-31 | ||
| EP19211404.9 | 2019-11-26 | ||
| EP19211404 | 2019-11-26 | ||
| PCT/EP2020/058637 WO2020201038A1 (en) | 2019-03-29 | 2020-03-27 | Inhaled administration of lipocalin muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526367A JP2022526367A (ja) | 2022-05-24 |
| JPWO2020201038A5 true JPWO2020201038A5 (enExample) | 2023-04-03 |
Family
ID=70292935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557778A Withdrawn JP2022526367A (ja) | 2019-03-29 | 2020-03-27 | リポカリンムテインの吸入投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168387A1 (enExample) |
| EP (1) | EP3946417A1 (enExample) |
| JP (1) | JP2022526367A (enExample) |
| KR (1) | KR20210146999A (enExample) |
| CN (1) | CN113939307A (enExample) |
| AU (1) | AU2020253034A1 (enExample) |
| CA (1) | CA3127973A1 (enExample) |
| WO (1) | WO2020201038A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| TW202241490A (zh) * | 2020-12-18 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| SG173332A1 (en) | 2006-08-01 | 2011-08-29 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CN101932598B (zh) | 2008-01-30 | 2016-12-21 | 皮里斯股份公司 | 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| EP3660510A3 (en) * | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| HRP20190689T1 (hr) * | 2010-06-08 | 2019-06-14 | Pieris Pharmaceuticals Gmbh | Muteini suznog lipokalina koji vežu il-4r alfa |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| US9260492B2 (en) * | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| WO2012072806A1 (en) | 2010-12-02 | 2012-06-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for ctla-4 |
| EP2791684B1 (en) * | 2011-12-12 | 2017-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| US9572863B2 (en) * | 2011-12-13 | 2017-02-21 | Pieris Pharmaceuticals Gmbh | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
| JP6420664B2 (ja) * | 2012-01-09 | 2018-11-14 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 障害を予防、処置、または診断するための方法 |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| KR20150131151A (ko) | 2013-03-14 | 2015-11-24 | 다이이찌 산쿄 가부시키가이샤 | 피씨에스케이9에 대한 신규의 결합 단백질 |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US10774119B2 (en) * | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
| AU2016212087B2 (en) | 2015-01-28 | 2019-11-07 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| CA2980840A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| RS64002B1 (sr) * | 2015-05-18 | 2023-03-31 | Pieris Pharmaceuticals Gmbh | Anti-kancerski fuzioni polipeptid |
| EP3115371A1 (en) * | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| CA2988831A1 (en) * | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| SG11201906509WA (en) * | 2017-01-18 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| RS64343B9 (sr) * | 2018-07-31 | 2023-11-30 | Pieris Pharmaceuticals Gmbh | Novi fuzioni protein specifičan za cd137 i pd-l1 |
| CN112955221A (zh) * | 2018-08-27 | 2021-06-11 | 皮里斯制药有限公司 | 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途 |
| WO2020173897A1 (en) * | 2019-02-26 | 2020-09-03 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| CA3133422A1 (en) * | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| JP2023527908A (ja) * | 2020-06-05 | 2023-06-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | ４－１ｂｂをターゲティングする多量体免疫調節物質 |
| WO2022058505A1 (en) * | 2020-09-18 | 2022-03-24 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
-
2020
- 2020-03-27 WO PCT/EP2020/058637 patent/WO2020201038A1/en not_active Ceased
- 2020-03-27 AU AU2020253034A patent/AU2020253034A1/en not_active Abandoned
- 2020-03-27 CA CA3127973A patent/CA3127973A1/en active Pending
- 2020-03-27 US US17/599,765 patent/US20220168387A1/en not_active Abandoned
- 2020-03-27 CN CN202080025546.6A patent/CN113939307A/zh active Pending
- 2020-03-27 JP JP2021557778A patent/JP2022526367A/ja not_active Withdrawn
- 2020-03-27 EP EP20719569.4A patent/EP3946417A1/en not_active Withdrawn
- 2020-03-27 KR KR1020217035440A patent/KR20210146999A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| ES2780127T3 (es) | Formulación superfina de formoterol | |
| JP2021193091A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| CN102325532B (zh) | 用于减轻肺部炎症的左氧氟沙星吸入剂 | |
| JP2023086774A (ja) | 乾燥粉末配合および使用方法 | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| KR20100091970A (ko) | 파킨슨병 치료용 조성물 | |
| WO2017027402A1 (en) | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders | |
| WO2017027387A1 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| WO2018017434A1 (en) | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| AU2021261049A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| WO2015014209A1 (zh) | 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用 | |
| Jin et al. | RETRACTED: Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases | |
| CN110505873B (zh) | 鼻内肾上腺素制剂及治疗疾病的方法 | |
| Sheikh et al. | Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment? | |
| CN106667974A (zh) | 一种吸入用硫酸特布他林溶液制备方法 | |
| JP2019516797A5 (enExample) | ||
| JP2023551989A (ja) | 生成物送達デバイス及び方法 | |
| JPWO2020201038A5 (enExample) | ||
| CN118806738A (zh) | 一种吸入施用的药物制剂及其在医药上的应用 | |
| WO2001015777A1 (en) | Pulmonary-administration of mineral ascorbates | |
| JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
| US20230041980A1 (en) | Method of protecting a respiratory tract or a lung from damage, method of protecting a lung from pressure damage induced by a ventilator, method of suppressing spread of infection with viruses or bacteria that cause pneumonia in pulmonary bronchial epithelial cells or alveolar epithelial cells, and nasal spray |